If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00089583","ctis_id":"","HasResults":"true","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"Non-randomized","arm_groups":[{"arm_group_label":"2 - 18 yrs old (FPV/RTV BID)","arm_group_description":"Cohort 1B - 2 - less than 6yrs old (FPV/RTV BID) Cohort 2 - 6 to less than 12 yrs old (FPV/RTV BID) Cohort 3 - 12 - 18 yrs old (FPV/RTV BID) Cohort 4 - 2 - 18 yrs (FPV/RTV BID)","arm_type":"Experimental"},{"arm_group_label":"2 - less than 6yrs old (FPV BID)","arm_group_description":"Cohort 1A - 2 - less than 6yrs old (FPV BID)","arm_type":"Experimental"}],"assignment":"Parallel Assignment","brief_summary":"This is a 48-week study to collect information on the safety and activity of an investigational medicine in patients, ages 2 to 18 years old, with HIV infection .","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus I","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:41:34","criteria":"Inclusion criteria: - Males or females 2 to 18 years of age Cohorts 1A and 1B, up to one month before 6th birthday at Baseline/Day 1 Cohort 2, up to one month before 12th birthday at Baseline/Day 1 Cohort 3, up to one month before 19th birthday at Baseline/Day 1 - A female is eligible to enter and participate in this study if she is of: a. non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is pre-menarchial); or, b. child-bearing potential with a negative serum pregnancy test at screen, a negative urine pregnancy test on Day 1 and who agrees to use one of the following methods of contraception (any contraception method must be used consistently and correctly, i.e., in accordance with both the product label and the instructions of a physician). Premenarchial females who develop child-bearing potential while on the study will be expected to follow one of the methods of contraception listed below. Agreement for complete abstinence from intercourse from 2 weeks prior to administration of study drugs, throughout the study and for 2 weeks after discontinuation of all study medications. Should a female subject of childbearing potential decide to become sexually active during the course of the study, she must be counseled and be willing to use one of the contraception methods listed below: Double barrier contraception (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide) Any intrauterine device (IUD) with published data showing that the expected failure rate is less than 1% per year (not all IUDs meet this criterion) Any other method with published data showing that the lowest expected failure rate for that method is less than 1% per year. Hormonal contraception is not recommended, due to decreased efficacy of contraception as well as increased risk of hepatic transaminase elevation (see Section 8.2). All subjects of childbearing potential or developing child-bearing potential while participating in this study should be counseled on the practice of safe/safer sex. - Parent or legal guardian (and subject whenever possible) has the ability to understand and provide written informed consent for the subject to participate in the trial. Verbal witnessed assent must be obtained from the subject whenever possible. - Screening plasma HIV-1 RNA >=400copies/mL. - Subjects must meet one of the following criterion: Antiretroviral therapy (ART)-naïve or PI-naïve subjects (defined as having received less than one week of any PI and any length of therapy with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and/or Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)). PI-experienced subjects (defined as having received greater than one week prior PI therapy with no more than three PIs). Prior RTV boosted PI therapy will be considered as only one PI as long as the RTV dose was lower than that recommended for use of RTV as an antiretroviral age Exclusion criteria: - Prior history of having received APV or FPV for >7 days. - NNRTI use within 14 days prior to study drug administration or anticipated need for concurrent NNRTI therapy during the treatment period of the study. - Subjects who, in the investigator's opinion, are not able to comply with the requirements of the study. - Subject is in the initial acute phase of a Centers for Disease Control and Prevention (CDC) Clinical Category C event or infection (per 1994 classification) at Baseline. Subject may be enrolled provided they are receiving treatment for the infection, such treatment not being contraindicated with FPV, and the subjects are clinically improving at the Baseline visit. - Presence of a malabsorption syndrome or other gastrointestinal dysfunction which might interfere with drug absorption or render the subject unable to take oral medication. - Pregnant or lactating females. - Presence of any serious medical condition (e.g., hemoglobinopathy, chronic anemia, a history of insulin resistance, diabetes, cardiac dysfunction, hepatitis or clinically relevant pancreatitis) which, in the opinion of the investigator, might compromise the safety of the subject. - Grade 3 or 4 transaminase levels (ALT and/or AST) within 28 days prior to study drug administration and/or clinically relevant episodes of hepatitis within the previous 6 months. - Any acute laboratory abnormality at screen which, in the opinion of the investigator, should preclude the subject's participation in the study of an investigational compound. If subjects are found to have an acute Grade 4 laboratory abnormality at screening, this test may be repeated once within the screening window. Any verified Grade 4 laboratory abnormality at screen would exclude a subject from study participation. - Treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days of study drug administration or an anticipated need for such treatment within the study period. - Treatment with immunomodulating agents (e.g., systemic corticosteroids, interleukins, interferons) or any agent with known anti-HIV activity (e.g., hydroxyurea or foscarnet) within 28 days of study drug administration. - Treatment with any of the following medications within 28 days prior to receiving study medication or the anticipated need during the study: Drugs whose plasma concentration may be increased to unsafe levels when co-administered with FPV including: Amiodarone, astemizole, bepridil, cisapride, dihydroergotamine, ergonovine, ergotamine, flecainide, halofantrine, lidocaine, lovastatin, methylergonovine, midazolam, pimozide, propafenone, quinidine, simvastatin, terfenadine, and triazolam Drugs with the potential to significantly decrease plasma APV concentrations including: Carbamazepine, dexamethasone, phenobarbital, primidone, rifampin, St Johns Wort. - Treatment with other investigational drugs/therapies (note: treatments available through a Treatment Investigational New Drug [IND] or other expanded-access mechanism will be evaluated on a case-by-case basis in consultation with the sponsor) within 28 days prior to study drug administration or during the treatment period of the study. - History of drug or other allergy which, in the opinion of the investigator, contraindicates participation in the trial or known hypersensitivity to any study medications (e.g., documented hypersensitivity to a nucleoside analogue). - Substantial non-adherence based on history","detailed_description":"A 48 Week, Phase II, non-comparative, open-label, multi-cohort, multicenter study to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of GW433908/Ritonavir BID when administered to HIV-1 infected PI-Naive and experienced, Pediatric Subjects 2 to 18 years old and of GW433908 BID Administered to PI-Naive Pediatric subjects 2 to <6 years old","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 2","display_phase_internal":"PHASE_2","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"110","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"6df7ce05-3941-514f-b978-0034d81ba061","internal":{"content":null,"contentDigest":"24f58227bd681aede7f6d0465227daf9","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion criteria: - Males or females 2 to 18 years of age Cohorts 1A and 1B, up to one month before 6th birthday at Baseline/Day 1 Cohort 2, up to one month before 12th birthday at Baseline/Day 1 Cohort 3, up to one month before 19th birthday at Baseline/Day 1 - A female is eligible to enter and participate in this study if she is of: a. non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is pre-menarchial); or, b. child-bearing potential with a negative serum pregnancy test at screen, a negative urine pregnancy test on Day 1 and who agrees to use one of the following methods of contraception (any contraception method must be used consistently and correctly, i.e., in accordance with both the product label and the instructions of a physician). Premenarchial females who develop child-bearing potential while on the study will be expected to follow one of the methods of contraception listed below. Agreement for complete abstinence from intercourse from 2 weeks prior to administration of study drugs, throughout the study and for 2 weeks after discontinuation of all study medications. Should a female subject of childbearing potential decide to become sexually active during the course of the study, she must be counseled and be willing to use one of the contraception methods listed below: Double barrier contraception (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide) Any intrauterine device (IUD) with published data showing that the expected failure rate is less than 1% per year (not all IUDs meet this criterion) Any other method with published data showing that the lowest expected failure rate for that method is less than 1% per year. Hormonal contraception is not recommended, due to decreased efficacy of contraception as well as increased risk of hepatic transaminase elevation (see Section 8.2). All subjects of childbearing potential or developing child-bearing potential while participating in this study should be counseled on the practice of safe/safer sex. - Parent or legal guardian (and subject whenever possible) has the ability to understand and provide written informed consent for the subject to participate in the trial. Verbal witnessed assent must be obtained from the subject whenever possible. - Screening plasma HIV-1 RNA >=400copies/mL. - Subjects must meet one of the following criterion: Antiretroviral therapy (ART)-naïve or PI-naïve subjects (defined as having received less than one week of any PI and any length of therapy with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and/or Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)). PI-experienced subjects (defined as having received greater than one week prior PI therapy with no more than three PIs). Prior RTV boosted PI therapy will be considered as only one PI as long as the RTV dose was lower than that recommended for use of RTV as an antiretroviral age Exclusion criteria: - Prior history of having received APV or FPV for >7 days. - NNRTI use within 14 days prior to study drug administration or anticipated need for concurrent NNRTI therapy during the treatment period of the study. - Subjects who, in the investigator's opinion, are not able to comply with the requirements of the study. - Subject is in the initial acute phase of a Centers for Disease Control and Prevention (CDC) Clinical Category C event or infection (per 1994 classification) at Baseline. Subject may be enrolled provided they are receiving treatment for the infection, such treatment not being contraindicated with FPV, and the subjects are clinically improving at the Baseline visit. - Presence of a malabsorption syndrome or other gastrointestinal dysfunction which might interfere with drug absorption or render the subject unable to take oral medication. - Pregnant or lactating females. - Presence of any serious medical condition (e.g., hemoglobinopathy, chronic anemia, a history of insulin resistance, diabetes, cardiac dysfunction, hepatitis or clinically relevant pancreatitis) which, in the opinion of the investigator, might compromise the safety of the subject. - Grade 3 or 4 transaminase levels (ALT and/or AST) within 28 days prior to study drug administration and/or clinically relevant episodes of hepatitis within the previous 6 months. - Any acute laboratory abnormality at screen which, in the opinion of the investigator, should preclude the subject's participation in the study of an investigational compound. If subjects are found to have an acute Grade 4 laboratory abnormality at screening, this test may be repeated once within the screening window. Any verified Grade 4 laboratory abnormality at screen would exclude a subject from study participation. - Treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days of study drug administration or an anticipated need for such treatment within the study period. - Treatment with immunomodulating agents (e.g., systemic corticosteroids, interleukins, interferons) or any agent with known anti-HIV activity (e.g., hydroxyurea or foscarnet) within 28 days of study drug administration. - Treatment with any of the following medications within 28 days prior to receiving study medication or the anticipated need during the study: Drugs whose plasma concentration may be increased to unsafe levels when co-administered with FPV including: Amiodarone, astemizole, bepridil, cisapride, dihydroergotamine, ergonovine, ergotamine, flecainide, halofantrine, lidocaine, lovastatin, methylergonovine, midazolam, pimozide, propafenone, quinidine, simvastatin, terfenadine, and triazolam Drugs with the potential to significantly decrease plasma APV concentrations including: Carbamazepine, dexamethasone, phenobarbital, primidone, rifampin, St Johns Wort. - Treatment with other investigational drugs/therapies (note: treatments available through a Treatment Investigational New Drug [IND] or other expanded-access mechanism will be evaluated on a case-by-case basis in consultation with the sponsor) within 28 days prior to study drug administration or during the treatment period of the study. - History of drug or other allergy which, in the opinion of the investigator, contraindicates participation in the trial or known hypersensitivity to any study medications (e.g., documented hypersensitivity to a nucleoside analogue). - Substantial non-adherence based on history","interventions":[{"arm_group_label":"2 - less than 6yrs old (FPV BID)","intervention_description":"Fosamprenavir suspension or tablet bid","intervention_name":"LEXIVA (GW433908)","intervention_type":"Drug"},{"arm_group_label":"2 - 18 yrs old (FPV/RTV BID)","intervention_description":"Fosamprenavir suspension or tablet bid","intervention_name":"LEXIVA (GW433908)","intervention_type":"Drug"},{"arm_group_label":"2 - 18 yrs old (FPV/RTV BID)","intervention_description":"Ritonavir solution bid","intervention_name":"Ritonavir","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":["antiretroviral therapy","pediatrics","AGENERASE","amprenavir","fosamprenavir","HIV Infection","ritonavir","protease inhibitor","LEXIVA"],"last_follow_up_date":"07/01/2013 00:00:00","links":[],"locations":[{"City":"Vancouver","Latitude":"49.2449191","CountryDisplay":"Canada","Longitude":"-123.1266581","Name":"GSK Investigational Site","StateDisplay":"British Columbia","PostalCode":"V6H 3N1","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fort Worth","Latitude":"32.7248887","CountryDisplay":"United States","Longitude":"-97.3138554","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"76104","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dallas","Latitude":"32.8296623","CountryDisplay":"United States","Longitude":"-96.8511814","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75235","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Barcelona","Latitude":"41.3842701","CountryDisplay":"Spain","Longitude":"2.1855573","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"08003","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Durban","Latitude":"-29.8695425","CountryDisplay":"South Africa","Longitude":"31.000537","Name":"GSK Investigational Site","StateDisplay":"KwaZulu- Natal","PostalCode":"4013","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"New York","Latitude":"40.74727","CountryDisplay":"United States","Longitude":"-73.9800645","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10016","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Palma de Mallorca","Latitude":"39.5683645","CountryDisplay":"Spain","Longitude":"2.6114849","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"07014","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Jacksonville","Latitude":"30.3617348","CountryDisplay":"United States","Longitude":"-81.6966306","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32209","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bronx","Latitude":"40.8441387","CountryDisplay":"United States","Longitude":"-73.8977693","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10457","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"New Hyde Park","Latitude":"40.7572158","CountryDisplay":"United States","Longitude":"-73.6962948","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"11042","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Parow Valley","Latitude":"-33.9137443","CountryDisplay":"South Africa","Longitude":"18.5908437","Name":"GSK Investigational Site","StateDisplay":"Western Province","PostalCode":"7505","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Boston","Latitude":"42.3600825","CountryDisplay":"United States","Longitude":"-71.0588801","Name":"GSK Investigational Site","StateDisplay":"Massachusetts","PostalCode":"02115-5724","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Madrid","Latitude":"40.3672276","CountryDisplay":"Spain","Longitude":"-3.6978264","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28041","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Durham","Latitude":"36.0038131","CountryDisplay":"United States","Longitude":"-78.9387241","Name":"GSK Investigational Site","StateDisplay":"North Carolina","PostalCode":"27710","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Philadelphia","Latitude":"39.9863531","CountryDisplay":"United States","Longitude":"-75.1019942","Name":"GSK Investigational Site","StateDisplay":"Pennsylvania","PostalCode":"19134","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Los Angeles","Latitude":"34.0502898","CountryDisplay":"United States","Longitude":"-118.2117257","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90033","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Toronto","Latitude":"43.6570957","CountryDisplay":"Canada","Longitude":"-79.3877344","Name":"GSK Investigational Site","StateDisplay":"Ontario","PostalCode":"M5G 1X8","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bucharest","Latitude":"44.4267674","CountryDisplay":"Romania","Longitude":"26.1025384","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"030303","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Malaga","Latitude":"36.7226027","CountryDisplay":"Spain","Longitude":"-4.467102","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"29010","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Oakland","Latitude":"37.8321173","CountryDisplay":"United States","Longitude":"-122.2625529","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94609","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"St. Petersburg","Latitude":"59.8404778","CountryDisplay":"Russia","Longitude":"30.5964013","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"196645","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Madrid","Latitude":"40.4731818","CountryDisplay":"Spain","Longitude":"-3.6864121","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28046","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Valencia","Latitude":"39.4845265","CountryDisplay":"Spain","Longitude":"-0.380721","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"46009","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Coronationville","Latitude":"-26.1925485","CountryDisplay":"South Africa","Longitude":"27.9761531","Name":"GSK Investigational Site","StateDisplay":"Gauteng","PostalCode":"2112","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Sevilla","Latitude":"37.3552204","CountryDisplay":"Spain","Longitude":"-5.9673967","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"41013","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bucharest","Latitude":"44.4267674","CountryDisplay":"Romania","Longitude":"26.1025384","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"021105","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Barcelona","Latitude":"41.3772561","CountryDisplay":"Spain","Longitude":"2.0910377","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"08950","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Montreal","Latitude":"45.5017244","CountryDisplay":"Canada","Longitude":"-73.625394","Name":"GSK Investigational Site","StateDisplay":"Québec","PostalCode":"H3T 1C5","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Birmingham","Latitude":"33.5118197","CountryDisplay":"United States","Longitude":"-86.8011326","Name":"GSK Investigational Site","StateDisplay":"Alabama","PostalCode":"35233","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tampa","Latitude":"27.926156","CountryDisplay":"United States","Longitude":"-82.4563199","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33606","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Moscow","Latitude":"55.7868312","CountryDisplay":"Russia","Longitude":"37.6332752","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"129110","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Winnipeg","Latitude":"49.9034452","CountryDisplay":"Canada","Longitude":"-97.1593064","Name":"GSK Investigational Site","StateDisplay":"Manitoba","PostalCode":"R3E 3P4","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Antwerpen","Latitude":"51.1890846","CountryDisplay":"Belgium","Longitude":"4.3836284","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"2020","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Boston","Latitude":"42.3377967","CountryDisplay":"United States","Longitude":"-71.0705763","Name":"GSK Investigational Site","StateDisplay":"Massachusetts","PostalCode":"02118","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Moscow","Latitude":"55.766642","CountryDisplay":"Russia","Longitude":"37.7393379","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"105275","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"New York","Latitude":"40.8140369","CountryDisplay":"United States","Longitude":"-73.9374517","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10037","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Soweto","Latitude":"-26.2485377","CountryDisplay":"South Africa","Longitude":"27.8540323","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"2013","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"New York","Latitude":"40.7700703","CountryDisplay":"United States","Longitude":"-73.9580246","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10021","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Vigo ( Pontevedra)","Latitude":"42.2281199","CountryDisplay":"Spain","Longitude":"-8.7164592","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"36204","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"Open Label","maximum_age_raw":"18 years","maximum_age":"18","minimum_age":"2","minimum_age_raw":"2 years","modified_date":"10/01/2018 22:59:51","number_of_arms":"2","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A 48 Week, Phase II, Non-Comparative, Open-label, Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir BID when Administered to HIV-1 infected, PI-Naïve and Experienced, Pediatric Subjects, 2 to 18 Years Old and of GW433908 BID Administered to PI-Naïve, Pediatric Subjects 2 to < 6 Years Old","org_study_id":"APV29005","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"None","fda_regulated_drug":"None","ped_postmarket_surv":"","has_dmc":true,"post_prior_to_approval":"None","regulatory_authorities":[""]},"phase":"2","primary_compl_date":"03/01/2011 00:00:00","primary_outcomes":[],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GSK"]},"start_date":"07/01/2004 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[{"citation":"Voronin E, Fortuny C, Perez-Tamarit D, et al. Pharmacokinetics, safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2 to 18 year-old children (48-week data, Study APV29005, a prospective, open-label, multi-centre, 48-week cohort study). Presented at: AIDS 2012 - 19th International AIDS Conference; July 22-27, 2012; Washington, DC.","is_results_ref":"None","pubmed_id":""},{"citation":"Ross L, Cotton M, Cassim H, et al. HIV-1 drug resistance and mutational profile in fosamprenavir-treated HIV-infected children aged 2 months to 18 years at start of therapy. Presented at: AIDS 2012 - 19th International AIDS Conference; July 22-27, 2012; Washington DC.","is_results_ref":"None","pubmed_id":""},{"citation":"Fortuny C, Duiculescu D, Cheng K, et al. Pharmacokinetics and 48 week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2 to 18 year-old children. Pediatr Infect Dis J.","is_results_ref":"Yes","pubmed_id":""}],"is_section_801":true}},"pageContext":{"studyId":"APV29005"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}